XyloCor Therapeutics
PrivateLast Round
Series B
Jan 7, 2025
Est. Valuation
$130M
Total Funding Raised
$107.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
XyloCor Therapeutics is a biotechnology company developing gene therapies for patients with advanced coronary artery disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
XyloCor Therapeutics Comparables
Compare XyloCor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gene Biotherapeutics Inc. | 80% | |
| Nuevocor | 77% | |
| Renova Therapeutics | 76% | |
XyloCor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 7, 2025 | ||||
| Series A Extension | Mar 22, 2021 | ||||
| Series A | Dec 6, 2018 |
XyloCor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series A Extension, Series B, Series A |
| Fountain Healthcare Partners | Series B, Series A Extension |
| EQT AB | Series B |
| Lumira Ventures | Series A Extension, Series B |
| Longwood Fund | Series A Extension |
| Jeito Capital | Series B |
| Sofinnova Investments | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
John Tucker appointed as new President and Chief Executive Officer.
- Jan 8, 2025
Rachel Mears, Partner at Jeito Capital, joins the board.
XyloCor Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about XyloCor Therapeutics's valuation, stock price, and market status.